Back to search

Article

Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice

2023-08-02

Abstract excerpt

Current COVID-19 vaccines can effectively reduce disease severity and hospitalisation; however, they are not considerably effective in preventing infection and transmission. In this context, mucosal vaccines are pertinent to prevent SARS-CoV-2 infection and spread. In this study, we generated a replication-competent recombinant chimeric influenza A virus (IAV) expressing the receptor-binding domain (RBD) of SARS-C...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
635ca69a-5354-52d0-ab33-8de146d6e5ef
DOI
10.20944/preprints202308.0071.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in MiceDOI 10.20944/preprints202308.0071.v1
Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Semantic proximity
Development of attenuated coxsackievirus B3 vectored intranasal pre-emptive pan-coronavirus vaccineSemantic proximity
Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like BetacoronavirusesSemantic proximity
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Semantic proximity
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in miceSemantic proximity
M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in miceSemantic proximity
Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concernSemantic proximity
Intranasal delivery of NS1-deleted influenza virus vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory responseSemantic proximity
A live attenuated influenza virus-vectored intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 infectionSemantic proximity
An intranasal influenza virus-vectored vaccine blocks SARS-CoV-2 replication in respiratory tissues of mice and hamstersSemantic proximity
Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza VaccinesSemantic proximity
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in miceSemantic proximity
Select a neighboring publication to make it the new centre.